Literature DB >> 16331268

Physical and functional interactions between Daxx and STAT3.

R Muromoto1, K Nakao, T Watanabe, N Sato, Y Sekine, K Sugiyama, K Oritani, K Shimoda, T Matsuda.   

Abstract

Signal transducer and activator of transcription 3 (STAT3) play key roles in the intracellular signaling pathways of the interleukin (IL)-6 family of cytokines, which exhibit a diverse set of cellular responses, including cell proliferation and differentiation. Dysregulated IL-6/STAT3 signaling is involved in the pathogenesis of several diseases, for example autoimmune diseases and tumors. Type I interferon (IFN) induces the expression of proapoptotic genes and has been used in the clinical treatment of several tumors. In the present study, we found that type I IFN suppressed IL-6/STAT3-mediated transcription and gene expression. Furthermore, a type I IFN-induced protein, Daxx, also suppressed STAT3-mediated transcriptional activation, while overexpression of Daxx inhibited IL-6/STAT3-mediated gene expression. Importantly, small-interfering RNA-mediated reduction of Daxx expression enhanced IL-6/leukemia inhibitory factor (LIF)-induced STAT3-dependent transcription. Co-immunoprecipitation studies revealed a physical interaction between Daxx and STAT3 in transiently transfected 293T cells. We further found that Daxx and STAT3 were co-localized in the nucleus. These results indicate that Daxx may serve as a transcriptional regulator of type I IFN-mediated suppression of the IL-6/STAT3 signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16331268     DOI: 10.1038/sj.onc.1209235

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Effect of Daxx on cholesterol accumulation in hepatic cells.

Authors:  Qin-Hui Tuo; Lei Liang; Bing-Yang Zhu; Xuan Cao; Duan-Fang Liao
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

Review 2.  Signal transducer and activator of transcription 3 regulation by novel binding partners.

Authors:  Tadashi Matsuda; Ryuta Muromoto; Yuichi Sekine; Sumihito Togi; Yuichi Kitai; Shigeyuki Kon; Kenji Oritani
Journal:  World J Biol Chem       Date:  2015-11-26

3.  CUEDC2 (CUE domain-containing 2) and SOCS3 (suppressors of cytokine signaling 3) cooperate to negatively regulate Janus kinase 1/signal transducers and activators of transcription 3 signaling.

Authors:  Wei-Na Zhang; Li Wang; Qiong Wang; Xue Luo; Di-Feng Fang; Yuan Chen; Xin Pan; Jiang-Hong Man; Qing Xia; Bao-Feng Jin; Wei-Hua Li; Tao Li; Bing Liang; Liang Chen; Wei-Li Gong; Ming Yu; Ai-Ling Li; Tao Zhou; Hui-Yan Li
Journal:  J Biol Chem       Date:  2011-11-14       Impact factor: 5.157

4.  HIC1 interacts with and modulates the activity of STAT3.

Authors:  Ying-Mei Lin; Chia-Mei Wang; Jen-Chong Jeng; Dominique Leprince; Hsiu-Ming Shih
Journal:  Cell Cycle       Date:  2013-07-15       Impact factor: 4.534

5.  A New STAT3-binding Partner, ARL3, Enhances the Phosphorylation and Nuclear Accumulation of STAT3.

Authors:  Sumihito Togi; Ryuta Muromoto; Koki Hirashima; Yuichi Kitai; Taichiro Okayama; Osamu Ikeda; Naoki Matsumoto; Shigeyuki Kon; Yuichi Sekine; Kenji Oritani; Tadashi Matsuda
Journal:  J Biol Chem       Date:  2016-04-05       Impact factor: 5.157

Review 6.  Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?.

Authors:  Bharat B Aggarwal; Ajaikumar B Kunnumakkara; Kuzhuvelil B Harikumar; Shan R Gupta; Sheeja T Tharakan; Cemile Koca; Sanjit Dey; Bokyung Sung
Journal:  Ann N Y Acad Sci       Date:  2009-08       Impact factor: 5.691

7.  Inhibition of STAT3-interacting protein 1 (STATIP1) promotes STAT3 transcriptional up-regulation and imatinib mesylate resistance in the chronic myeloid leukemia.

Authors:  André L Mencalha; Stephany Corrêa; Daniela Salles; Bárbara Du Rocher; Marcelo F Santiago; Eliana Abdelhay
Journal:  BMC Cancer       Date:  2014-11-23       Impact factor: 4.430

Review 8.  STAT3 Interactors as Potential Therapeutic Targets for Cancer Treatment.

Authors:  Federica Laudisi; Fabio Cherubini; Giovanni Monteleone; Carmine Stolfi
Journal:  Int J Mol Sci       Date:  2018-06-16       Impact factor: 5.923

Review 9.  DAXX in cancer: phenomena, processes, mechanisms and regulation.

Authors:  Iqbal Mahmud; Daiqing Liao
Journal:  Nucleic Acids Res       Date:  2019-09-05       Impact factor: 16.971

10.  Epigenetic silencing of the NR4A3 tumor suppressor, by aberrant JAK/STAT signaling, predicts prognosis in gastric cancer.

Authors:  Chung-Min Yeh; Liang-Yu Chang; Shu-Hui Lin; Jian-Liang Chou; Hsiao-Yen Hsieh; Li-Han Zeng; Sheng-Yu Chuang; Hsiao-Wen Wang; Claudia Dittner; Cheng-Yu Lin; Jora M J Lin; Yao-Ting Huang; Enders K W Ng; Alfred S L Cheng; Shu-Fen Wu; Jiayuh Lin; Kun-Tu Yeh; Michael W Y Chan
Journal:  Sci Rep       Date:  2016-08-16       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.